targeted cancer therapy companies

Companies whose enriched business profile is tagged “targeted cancer therapy”, drawn from their SEC filings + website text. Sorted by market capitalization; every figure is delayed data from SEC EDGAR + market data, shown with its as-of date.

• Revolution Medicines (RVMD) Health Care — Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform. ask →
• TANGO THERAPEUTICS INC (TNGX) Health Care — A precision oncology firm using a proprietary functional genomics platform to discover and develop targeted small-molecule therapies for genetically defined cancers. ask →
• CELCUITY INC (CELC) Health Care — Celcuity is a biotechnology company developing gedatolisib, a targeted PI3K/mTOR inhibitor, to treat various cancer indications. ask →
• IMMUNOME INC (IMNM) Health Care — Immunome is a clinical-stage biotechnology company leveraging a proprietary platform to discover and develop novel, targeted oncology therapeutics. ask →
• NUVATION BIO INC CLASS A (NUVB) Health Care — Nuvation Bio is a clinical-stage oncology firm advancing a portfolio of targeted small-molecule therapies for patients with solid tumors, highlighted by its ROS1-positive NSCLC treatment, IBTROZI. ask →
• SYNDAX PHARMACEUTICALS INC (SNDX) Health Care — A clinical-stage biopharmaceutical company developing targeted, small-molecule therapies to treat cancer and chronic graft-versus-host disease. ask →
• RIGEL PHARMACEUTICALS INC (RIGL) Health Care — A commercial-stage biotechnology company developing and marketing targeted therapies for hematologic malignancies and cancers. ask →
• PERSPECTIVE THERAPEUTICS INC (CATX) Health Care — A clinical-stage radiopharmaceutical company pioneering 212Pb-based alpha-emitter therapies and theranostics for precision oncology. ask →
• SUTRO BIOPHARMA INC (STRO) Health Care — Sutro Biopharma is pioneering a proprietary cell-free protein synthesis platform to develop next-generation, homogeneous antibody-drug conjugates for hard-to-treat solid tumors. ask →
• WHITEHAWK THERAPEUTICS INC (WHWK) Health Care — Clinical-stage oncology company developing a pipeline of next-generation antibody-drug conjugates targeting solid tumors. ask →
• KARYOPHARM THERAPEUTICS INC (KPTI) Health Care — Karyopharm Therapeutics develops novel cancer therapies using its proprietary XPO1 inhibition platform, with the lead drug XPOVIO currently used in multiple myeloma and a late-stage pipeline targeting myelofibrosis. ask →

Not quite it? Describe exactly what you want →

Data: SEC EDGAR (filings) + market data (fundamentals, delayed daily-close). Figures shown with their as-of date.

Last updated 2026-10-08.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.